Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Barclays Maintains Overweight on Core & Main, Lowers Price Target to $28

Barclays analyst Matthew Bouley maintains Core & Main (NYSE:CNM) with a Overweight and lowers the price target from $29 to $28.

byBenzinga Newsdesk

July 15, 2022

1 minute read

Barclays analyst Matthew Bouley maintains Core & Main (NYSE:CNM) with a Overweight and lowers the price target from $29 to $28.

Raymond James Maintains Strong Buy on Valero Energy, Raises Price Target to $95

By Benzinga Newsdesk

Today, 6:44 AM

Raymond James analyst Justin Jenkins maintains Valero Energy (NYSE:VLO) with a Strong Buy and raises the price target from $88 to $95.

VLO

Raymond James Maintains Strong Buy on Horizon Bancorp, Raises Price Target to $25

By Benzinga Newsdesk

Today, 6:44 AM

Raymond James analyst David Long maintains Horizon Bancorp (NASDAQ:HBNC) with a Strong Buy and raises the price target from $24 to $25.

HBNC

News

Sumo Logic: Return On Capital Employed Insights

By Benzinga Insights

Today, 6:44 AM

In Q1, Sumo Logic (NASDAQ:SUMO) posted sales of $54.22 million. Earnings were up 34.93%, but Sumo Logic still reported an overall loss of $26.47 million. In Q4, Sumo Logic brought in $54.15 million in sales but lost $19.62 million in earnings.

SUMO

Patient Death Prompts MacroGenics To Close Mid-Stage Head & Cancer Study

By Vandana Singh

Today, 6:44 AM

MacroGenics Inc (NASDAQ:MGNX) closed the Phase 2 study (CP-MGA271-06) of enoblituzumab in the first-line treatment of patients with recurrent or metastatic…

MGNX

Barclays Maintains Overweight on Core & Main, Lowers Price Target to $28

Related Posts

Raymond James Maintains Strong Buy on Valero Energy, Raises Price Target to $95

Raymond James Maintains Strong Buy on Horizon Bancorp, Raises Price Target to $25

Sumo Logic: Return On Capital Employed Insights

Patient Death Prompts MacroGenics To Close Mid-Stage Head & Cancer Study